Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D.
Schoenfeld JD, Azad NS, Gross J, Chen L, Overman MJ, Kao K, Jackson LF, Brunnquell D, Bu X, Coppola C, Guan P, Lee J, Sims D, Fuchs R, Weirather JL, Pfaff KL, Gunasti L, Ranasinghe S, Hamilton SR, Wang V, O'Dwyer PJ, Wu CJ, Rodig SJ, Patton DR, Harris L.
Schoenfeld JD, et al. Among authors: brunnquell d.
Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-0427. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 39670863